clemastine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihistaminics | 671 | 15686-51-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | mg | O |
| 2 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 2.30 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.39 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 37 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 25, 1977 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| General physical health deterioration | 87.99 | 24.18 | 82 | 4765 | 115687 | 46565528 |
| Leukopenia | 79.80 | 24.18 | 62 | 4785 | 68281 | 46612934 |
| Tooth erosion | 65.03 | 24.18 | 14 | 4833 | 465 | 46680750 |
| Allergy test positive | 64.10 | 24.18 | 13 | 4834 | 321 | 46680894 |
| Pulpitis dental | 57.94 | 24.18 | 14 | 4833 | 783 | 46680432 |
| Drug reaction with eosinophilia and systemic symptoms | 53.38 | 24.18 | 35 | 4812 | 29513 | 46651702 |
| Erythema | 52.23 | 24.18 | 69 | 4778 | 142751 | 46538464 |
| Angioedema | 48.73 | 24.18 | 37 | 4810 | 39305 | 46641910 |
| Dyspnoea | 46.98 | 24.18 | 138 | 4709 | 515410 | 46165805 |
| Anaphylactic shock | 41.52 | 24.18 | 26 | 4821 | 20248 | 46660967 |
| Periodontitis | 41.29 | 24.18 | 15 | 4832 | 3461 | 46677754 |
| Circulatory collapse | 39.99 | 24.18 | 26 | 4821 | 21598 | 46659617 |
| Toxic epidermal necrolysis | 39.28 | 24.18 | 26 | 4821 | 22252 | 46658963 |
| Mucosal inflammation | 38.30 | 24.18 | 32 | 4815 | 38944 | 46642271 |
| Nail toxicity | 35.11 | 24.18 | 8 | 4839 | 346 | 46680869 |
| Venous thrombosis limb | 29.03 | 24.18 | 11 | 4836 | 2852 | 46678363 |
| Postpartum haemorrhage | 26.08 | 24.18 | 9 | 4838 | 1788 | 46679427 |
| Sensory disturbance | 25.79 | 24.18 | 16 | 4831 | 12251 | 46668964 |
| Chills | 25.64 | 24.18 | 40 | 4807 | 95992 | 46585223 |
| Subileus | 25.00 | 24.18 | 10 | 4837 | 2993 | 46678222 |
| Cerebral hypoperfusion | 24.73 | 24.18 | 6 | 4841 | 341 | 46680874 |
| Leukocytosis | 24.62 | 24.18 | 20 | 4827 | 23378 | 46657837 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 45.84 | 23.29 | 26 | 2916 | 17914 | 29931622 |
| Febrile neutropenia | 35.77 | 23.29 | 48 | 2894 | 106645 | 29842891 |
| Long QT syndrome | 35.75 | 23.29 | 12 | 2930 | 2321 | 29947215 |
| Cytokine release syndrome | 35.50 | 23.29 | 18 | 2924 | 9915 | 29939621 |
| Pulpitis dental | 34.46 | 23.29 | 8 | 2934 | 398 | 29949138 |
| Leukopenia | 33.49 | 23.29 | 34 | 2908 | 56125 | 29893411 |
| Polyneuropathy | 32.55 | 23.29 | 18 | 2924 | 11805 | 29937731 |
| Lacrimal duct neoplasm | 32.19 | 23.29 | 5 | 2937 | 25 | 29949511 |
| Mantle cell lymphoma stage III | 32.19 | 23.29 | 5 | 2937 | 25 | 29949511 |
| Fibrin D dimer increased | 30.78 | 23.29 | 11 | 2931 | 2563 | 29946973 |
| Cancer fatigue | 30.63 | 23.29 | 5 | 2937 | 36 | 29949500 |
| Drug therapeutic incompatibility | 30.62 | 23.29 | 6 | 2936 | 131 | 29949405 |
| Pyrexia | 29.73 | 23.29 | 79 | 2863 | 294410 | 29655126 |
| Chills | 29.67 | 23.29 | 36 | 2906 | 72302 | 29877234 |
| Infusion related reaction | 28.74 | 23.29 | 27 | 2915 | 40537 | 29908999 |
| Electrocardiogram T wave biphasic | 28.64 | 23.29 | 5 | 2937 | 56 | 29949480 |
| Conjunctivitis | 27.14 | 23.29 | 14 | 2928 | 7986 | 29941550 |
| Distributive shock | 26.00 | 23.29 | 7 | 2935 | 639 | 29948897 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D04AA14 | DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Antihistamines for topical use |
| ATC | R06AA04 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Aminoalkyl ethers |
| ATC | R06AA54 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Aminoalkyl ethers |
| CHEBI has role | CHEBI:37955 | h1-receptor blockers |
| CHEBI has role | CHEBI:48876 | antimuskarinika |
| CHEBI has role | CHEBI:50857 | anti-allergic agents |
| CHEBI has role | CHEBI:59683 | anti-itching drug |
| MeSH PA | D018926 | Anti-Allergic Agents |
| MeSH PA | D000982 | Antipruritics |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D018494 | Histamine Agents |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006634 | Histamine H1 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dermatographic urticaria | indication | 7632005 | DOID:743 |
| Vasomotor rhinitis | indication | 8229003 | DOID:4730 |
| Allergic rhinitis | indication | 61582004 | |
| Nasal discharge | indication | 64531003 | |
| Nasal congestion | indication | 68235000 | |
| Sneezing | indication | 76067001 | |
| Urticaria | indication | 126485001 | |
| Itching of skin | indication | 418363000 | |
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Anaphylaxis Adjunct | indication | ||
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Chronic idiopathic constipation | contraindication | 82934008 | |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.7 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 8.59 | WOMBAT-PK | CHEMBL | |||
| D(1A) dopamine receptor | GPCR | Ki | 6.12 | DRUG MATRIX | |||||
| D(2) dopamine receptor | GPCR | Ki | 7.35 | DRUG MATRIX | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 7.16 | DRUG MATRIX | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.85 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.51 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 8.04 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.64 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.28 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 7.44 | DRUG MATRIX | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.85 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 8.60 | DRUG MATRIX | |||||
| Histamine H2 receptor | GPCR | Ki | 6.44 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 8.08 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.56 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 8.22 | DRUG MATRIX | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.85 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 6.27 | DRUG MATRIX | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 7.82 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 6.22 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.70 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.80 | WOMBAT-PK | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | Ki | 7.92 | WOMBAT-PK | |||||
| Cytochrome P450 2D6 | Enzyme | Ki | 5.70 | WOMBAT-PK | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 5.31 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 7.39 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.66 | DRUG MATRIX | |||||
| Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.35 | DRUG MATRIX | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 7.28 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019681 | VUID |
| N0000147773 | NUI |
| D00666 | KEGG_DRUG |
| 14976-57-9 | SECONDARY_CAS_RN |
| 4018759 | VANDF |
| 4019681 | VANDF |
| C0008929 | UMLSCUI |
| CHEBI:3738 | CHEBI |
| CHEMBL1626 | ChEMBL_ID |
| CHEMBL1200795 | ChEMBL_ID |
| DB00283 | DRUGBANK_ID |
| D002974 | MESH_DESCRIPTOR_UI |
| 26987 | PUBCHEM_CID |
| 6063 | IUPHAR_LIGAND_ID |
| 2231 | INN_ID |
| 95QN29S1ID | UNII |
| 142430 | RXNORM |
| 224 | MMSL |
| 4464 | MMSL |
| d00780 | MMSL |
| 003410 | NDDF |
| 004441 | NDDF |
| 372744005 | SNOMEDCT_US |
| 45218006 | SNOMEDCT_US |
| 83968007 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Clemastine Fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0308 | TABLET | 2.68 mg | ORAL | ANDA | 13 sections |
| Clemastine Fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51655-425 | TABLET | 2.68 mg | Oral | ANDA | 12 sections |
| Clemastine Fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54838-514 | SYRUP | 0.67 mg | ORAL | ANDA | 17 sections |
| Clemastine Fumarate | HUMAN OTC DRUG LABEL | 1 | 54868-5913 | TABLET | 1.34 mg | ORAL | ANDA | 14 sections |
| Clemastine Fumarate | HUMAN OTC DRUG LABEL | 1 | 68151-2456 | TABLET | 1.34 mg | ORAL | ANDA | 14 sections |
| Clemastine Fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73308-358 | SYRUP | 0.67 mg | ORAL | ANDA | 17 sections |